Literature DB >> 18621523

Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.

Adwoa Akwabi-Ameyaw1, Jonathan Y Bass, Richard D Caldwell, Justin A Caravella, Lihong Chen, Katrina L Creech, David N Deaton, Stacey A Jones, Istvan Kaldor, Yaping Liu, Kevin P Madauss, Harry B Marr, Robert B McFadyen, Aaron B Miller, Frank Navas, Derek J Parks, Paul K Spearing, Dan Todd, Shawn P Williams, G Bruce Wisely.   

Abstract

Starting from the known FXR agonist GW 4064 1a, a series of stilbene replacements were prepared. The 6-substituted 1-naphthoic acid 1b was an equipotent FXR agonist with improved developability parameters relative to 1a. Analog 1b also reduced the severity of cholestasis in the ANIT acute cholestatic rat model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18621523     DOI: 10.1016/j.bmcl.2008.06.073

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  32 in total

1.  Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.

Authors:  Anurima Majumder; Lakshmanan Govindasamy; Andrew Magis; Róbert Kiss; Tímea Polgár; Rebekah Baskin; Robert W Allan; Mavis Agbandje-McKenna; Gary W Reuther; György M Keseru; Kirpal S Bisht; Peter P Sayeski
Journal:  J Biol Chem       Date:  2010-07-28       Impact factor: 5.157

2.  Two farnesoid X receptor alpha isoforms in Japanese medaka (Oryzias latipes) are differentially activated in vitro.

Authors:  Deanna L Howarth; Lee R Hagey; Sheran H W Law; Ni Ai; Matthew D Krasowski; Sean Ekins; John T Moore; Erin M Kollitz; David E Hinton; Seth W Kullman
Journal:  Aquat Toxicol       Date:  2010-03-01       Impact factor: 4.964

3.  Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.

Authors:  Lulu Sun; Cen Xie; Guang Wang; Yue Wu; Qing Wu; Xuemei Wang; Jia Liu; Yangyang Deng; Jialin Xia; Bo Chen; Songyang Zhang; Chuyu Yun; Guan Lian; Xiujuan Zhang; Heng Zhang; William H Bisson; Jingmin Shi; Xiaoxia Gao; Pupu Ge; Cuihua Liu; Kristopher W Krausz; Robert G Nichols; Jingwei Cai; Bipin Rimal; Andrew D Patterson; Xian Wang; Frank J Gonzalez; Changtao Jiang
Journal:  Nat Med       Date:  2018-11-05       Impact factor: 53.440

4.  Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone.

Authors:  Liping Yang; David Broderick; Yuan Jiang; Victor Hsu; Claudia S Maier
Journal:  Biochim Biophys Acta       Date:  2014-06-18

5.  Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.

Authors:  Antonella Giancristofaro; Arménio J M Barbosa; Alessandra Ammazzalorso; Pasquale Amoia; Barbara De Filippis; Marialuigia Fantacuzzi; Letizia Giampietro; Cristina Maccallini; Rosa Amoroso
Journal:  Medchemcomm       Date:  2018-07-04       Impact factor: 3.597

6.  Lessons learned in induced fit docking and metadynamics in the Drug Design Data Resource Grand Challenge 2.

Authors:  Matthew P Baumgartner; David A Evans
Journal:  J Comput Aided Mol Des       Date:  2017-11-10       Impact factor: 3.686

7.  Combining self- and cross-docking as benchmark tools: the performance of DockBench in the D3R Grand Challenge 2.

Authors:  Veronica Salmaso; Mattia Sturlese; Alberto Cuzzolin; Stefano Moro
Journal:  J Comput Aided Mol Des       Date:  2017-08-24       Impact factor: 3.686

8.  Ligand binding and heterodimerization with retinoid X receptor α (RXRα) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding.

Authors:  Na Wang; Qingan Zou; Jinxin Xu; Jiancun Zhang; Jinsong Liu
Journal:  J Biol Chem       Date:  2018-10-01       Impact factor: 5.157

9.  Exposure to the synthetic FXR agonist GW4064 causes alterations in gene expression and sublethal hepatotoxicity in eleutheroembryo medaka (Oryzias latipes).

Authors:  Deanna L Howarth; Sheran H W Law; J McHugh Law; J A Mondon; Seth W Kullman; David E Hinton
Journal:  Toxicol Appl Pharmacol       Date:  2009-12-03       Impact factor: 4.219

10.  Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.

Authors:  Donna D Yu; Wenwei Lin; Taosheng Chen; Barry M Forman
Journal:  Bioorg Med Chem       Date:  2013-05-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.